Key statistics
On Monday, Castle Biosciences Inc (CSTL:NMQ) closed at 27.99, 91.84% above the 52 week low of 14.59 set on Aug 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 28.74 |
|---|---|
| High | 29.37 |
| Low | 27.73 |
| Bid | 27.68 |
| Offer | 29.99 |
| Previous close | 29.57 |
| Average volume | 520.37k |
|---|---|
| Shares outstanding | 29.73m |
| Free float | 28.89m |
| P/E (TTM) | -- |
| Market cap | 879.15m USD |
| EPS (TTM) | -0.4533 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
- Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
- Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
- Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
- Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
- Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
- Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
- New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
More ▼
